Business
Soligenix Announces Recent Accomplishments And First Quarter 2019 Financial Results
PRINCETON, N.J., May 14, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on
About this update from Soligenix, Inc.
[{"type":"text","content":" PRINCETON, N.J., May 14, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended March 31, 2019.\nChristopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix stated, \"We have completed the approximate 90 subject enrollment necessary to support the interim efficacy analysis of our pivotal double-blind, placebo-controlled Phase 3 clinical trial of SGX942 (dusquetide) for the treatment of oral mucositis in patients with head and neck cancer receiving chemoradiation therapy. This interim analysis, to be conducted by the independent Data Monitoring Committee (DMC) for the trial, is anticipated to occur in September 2019. We expect completion of full enrollment in the study in the second half of 2019, with final top-line results expected in the first half of 2020, pending the DMC recommendation.\" \nDr. Schaber continued, \"Following the positive recommendation received from the independent DMC for our double-blind, placebo-controlled Phase 3 study for the treatment of cutaneous T-cell lymphoma (CTCL) with SGX301 (synthetic hypericin), we continue to enroll patients and anticipate completing study enrollment in the second half of 2019, with final top-line results in the first quarter of 2020.\" \nSoligenix Recent Accomplishments: \nOn April 23, 2019, the Company issued an update letter from Dr. Schaber. This letter provided an update as well as further guidance on the development programs for 2019. To view this press release, please click here. On April 18, 2019, the Company announced it had reached a significant milestone in the Phase 3 clinical study (the \"DOM-INNATE\" study) for SGX942 (dusquetide) in the treatment of oral mucositis in patients with head and neck cancer. Patient enrollment is sufficient to support the planned interim efficacy analysis by the independent DMC. In accordance with the clinical protocol, approximately 90 subjects have been enrolled into the study as required for the planned interim efficacy analysis. To view this press release, please click here. On April 15, 2019, the Company announced it had received approximately $611,00...